Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 17/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582651 | 0.82 | MTNR1A (0.52) | MTNR1ANQO2MTNR1BHTR2CHTR2B | |
| SCHEMBL1882845 | 0.80 | HTR2A (0.68) | HTR2AMTNR1ANQO2MTNR1BHTR2C | |
| SCHEMBL27859804 | 0.77 | MTNR1A (0.54) | MTNR1ANQO2MTNR1B | |
| SCHEMBL6417161 | 0.76 | HTR2A (0.35) | HTR2AMTNR1ANQO2MTNR1BHTR2C | |
| SCHEMBL27876475 | 0.75 | MTNR1A (0.66) | MTNR1AMTNR1B | |
| SCHEMBL6410573 | 0.74 | MTNR1A (0.47) | MTNR1ANQO2 | |
| SCHEMBL15974659 | 0.74 | CYP4F2 (0.51) | — | |
| SCHEMBL31670075 | 0.72 | CYP2A6 (0.52) | HTR2AHTR2CHTR2B | |
| SCHEMBL6584082 | 0.72 | MTNR1A (0.38) | HTR2AMTNR1ANQO2MTNR1BHTR2C | |
| SCHEMBL2312110 | 0.72 | MTNR1A (0.39) | HTR2AMTNR1ANQO2MTNR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | BAYER HEALTHCARE AG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1414788-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003014064-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | AVPR1A, GRIN1, OPRL1 | HTR2A 140/4885MTNR1A 38/4885NQO2 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.